Altered hyaluronan biosynthesis and cancer progression: An immunological perspective

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 13, 2009, Pages 1538-1546

  Alaniz, Laura ^a,b   Garcia, Mariana ^a,b   Rizzo, Miguel ^a   Piccioni, Flavia ^a   Mazzolini, Guillermo ^a,b  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Cancer; CD44; Dendritic cells; Extracellular matrix; Hyaluronan; Immune system

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID;

BIOSYNTHESIS; CANCER GROWTH; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; DENDRITIC CELL; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SHORT SURVEY;

DISEASE PROGRESSION; HUMANS; HYALURONIC ACID; NEOPLASMS;

EID: 75449093214     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709790361485     Document Type: Short Survey

References (86)

1. Fraser, J. R.; Laurent, T. C.; Laurent, U. B. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med., 1997, 242, 27-33.
2. Itano, N. Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. J. Biochem., 2008, 144, 131-7.
3. Termeer, C.; Sleeman, J. P.; Simon, J. C. Hyaluronan--magic glue for the regulation of the immune response? Trends Immunol., 2003, 24, 112-4.
4. Stern, R. Hyaluronidases in cancer biology. Semin. Cancer Biol., 2008, 18, 275-80.
5. Laurent, T. C.; Laurent, U. B.; Fraser, J. R. The structure and function of hyaluronan: An overview. Immunol. Cell Biol., 1996, 74, A1-7.
6. Volpi, N.; Schiller, J.; Stern, R.; Soltes, L. Role, metabolism, chemical modifications and applications of hyaluronan. Curr. Med. Chem., 2009, 16, 1718-45.
7. Tammi, M. I.; Day, A. J.; Turley, E. A. Hyaluronan and homeostasis: a balancing act. J. Biol. Chem., 2002, 277, 4581-4.
8. Jiang, D.; Liang, J.; Noble, P. W. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol., 2007, 23, 435-61.
9. Weigel, P. H.; DeAngelis, P. L. Hyaluronan synthases: a decadeplus of novel glycosyltransferases. J. Biol. Chem., 2007, 282, 36777-81.
10. Stern, R.; Jedrzejas, M. J. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem. Rev., 2006, 106, 818-39.
11. Knudson, W.; Chow, G.; Knudson, C. B. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol., 2002, 21, 15-23.
12. Jackson, D. G. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS, 2004, 112, 526-38.
13. Day, A. J.; Prestwich, G. D. Hyaluronan-binding proteins: tying up the giant. J. Biol. Chem., 2002, 277, 4585-8.
14. Ponta, H.; Sherman, L.; Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol., 2003, 4, 33-45.
15. Wielenga, V. J.; Heider, K. H.; Offerhaus, G. J.; Adolf, G. R.; van den Berg, F. M.; Ponta, H.; Herrlich, P.; Pals, S. T. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res., 1993, 53, 4754-6.
16. Khan, S. A.; Cook, A. C.; Kappil, M.; Gunthert, U.; Chambers, A. F.; Tuck, A. B.; Denhardt, D. T. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel posttranscriptional, post-translational regulation. Clin. Exp. Metastasis, 2005, 22, 663-73.
17. Fox, S. B.; Fawcett, J.; Jackson, D. G.; Collins, I.; Gatter, K. C.; Harris, A. L.; Gearing, A.; Simmons, D. L. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res., 1994, 54, 4539-46.
18. Lesley, J.; Hascall, V. C.; Tammi, M.; Hyman, R. Hyaluronan binding by cell surface CD44. J. Biol. Chem., 2000, 275, 26967-75.
19. Zhou, B.; Weigel, J. A.; Saxena, A.; Weigel, P. H. Molecular cloning and functional expression of the rat 175-kDa hyaluronan receptor for endocytosis. Mol. Biol. Cell, 2002, 13, 2853-68.
20. Termeer, C.; Benedix, F.; Sleeman, J.; Fieber, C.; Voith, U.; Ahrens, T.; Miyake, K.; Freudenberg, M.; Galanos, C.; Simon, J. C. Oligosaccharides of Hyaluronan activate dendritic cells via tolllike receptor 4. J. Exp. Med., 2002, 195, 99-111.
21. Scheibner, K. A.; Lutz, M. A.; Boodoo, S.; Fenton, M. J.; Powell, J. D.; Horton, M. R. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol., 2006, 177, 1272-81.
22. Tesar, B. M.; Jiang, D.; Liang, J.; Palmer, S. M.; Noble, P. W.; Goldstein, D. R. The role of hyaluronan degradation products as innate alloimmune agonists. Am. J. Transplant., 2006, 6, 2622-35.
23. Toole, B. P. Hyaluronan in morphogenesis. Semin. Cell Dev. Biol., 2001, 12, 79-87.
24. Bastow, E. R.; Byers, S.; Golub, S. B.; Clarkin, C. E.; Pitsillides, A. A.; Fosang, A. J. Hyaluronan synthesis and degradation in cartilage and bone. Cell Mol. Life Sci., 2008, 65, 395-413.
25. Bourguignon, L. Y.; Singleton, P. A.; Zhu, H.; Diedrich, F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J. Biol. Chem., 2003, 278, 29420-34.
26. Toole, B. P.; Hascall, V. C. Hyaluronan and tumor growth. Am. J. Pathol., 2002, 16, 745-7.
27. Sohara, Y.; Ishiguro, N.; Machida, K.; Kurata, H.; Thant, A. A.; Senga, T.; Matsuda, S.; Kimata, K.; Iwata, H.; Hamaguchi, M. Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner. Mol. Biol. Cell, 2001, 12, 1859-68.
28. Camenisch, T. D.; Spicer, A. P.; Brehm-Gibson, T.; Biesterfeldt, J.; Augustine, M. L.; Calabro, A., Jr.; Kubalak, S.; Klewer, S. E.; McDonald, J. A. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest., 2000, 106, 349-60.
29. Ghatak, S.; Misra, S.; Toole, B. P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem., 2002, 277, 38013-20.
30. Alaniz, L.; Garcia, M. G.; Gallo-Rodriguez, C.; Agusti, R.; Sterin-Speziale, N.; Hajos, S. E.; Alvarez, E. Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-kappaB transcription factor. Glycobiology, 2006, 16, 359-67.
31. Evanko, S. P.; Wight, T. N. Intracellular localization of hyaluronan in proliferating cells. J. Histochem. Cytochem., 1999, 47, 1331-42.
32. Kujawa, M. J.; Pechak, D. G.; Fiszman, M. Y.; Caplan, A. I. Hyaluronic acid bonded to cell culture surfaces inhibits the program of myogenesis. Dev. Biol., 1986, 113, 10-6.
33. Li, Y.; Toole, B. P.; Dealy, C. N.; Kosher, R. A. Hyaluronan in limb morphogenesis. Dev. Biol., 2007, 305, 411-20.
34. Slevin, M.; Krupinski, J.; Gaffney, J.; Matou, S.; West, D.; Delisser, H.; Savani, R. C.; Kumar, S. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol., 2007, 26, 58-68.
35. Al Qteishat, A.; Gaffney, J. J.; Krupinski, J.; Slevin, M. Hyaluronan expression following middle cerebral artery occlusion in the rat. Neuroreport, 2006, 17, 1111-4.
36. Slevin, M.; Kumar, S.; Gaffney, J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J. Biol. Chem., 2002, 277, 41046-59.
37. Savani, R. C.; Cao, G.; Pooler, P. M.; Zaman, A.; Zhou, Z.; DeLisser, H. M. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J. Biol. Chem., 2001, 276, 36770-8.
38. Peyron, J. G.; Balazs, E. A. Preliminary clinical assessment of Nahyaluronate injection into human arthritic joints. Pathol. Biol. (Paris), 1974, 22, 731-6.
39. Dougados, M.; Nguyen, M.; Listrat, V.; Amor, B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage, 1993, 1, 97-103.
40. Moreland, L. W. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis. Res. Ther., 2003, 5, 54-67.
41. Chou, C. L.; Li, H. W.; Lee, S. H.; Tsai, K. L.; Ling, H. Y. Effect of intra-articular injection of hyaluronic acid in rheumatoid arthritis patients with knee osteoarthritis. J. Chin. Med. Assoc., 2008, 71, 411-5.
42. Balazs, E. A. Hyaluronan as an ophthalmic viscoelastic device. Curr. Pharm. Biotechnol., 2008, 9, 236-8.
43. Saika, S.; Ohnishi, Y.; Ooshima, A.; Liu, C. Y.; Kao, W. W. Epithelial repair: roles of extracellular matrix. Cornea, 2002, 21, S23-9.
44. Romagnoli, M.; Belmontesi, M. Hyaluronic acid-based fillers: theory and practice. Clin. Dermatol., 2008, 26, 123-59.
45. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer, 2005, 5, 263-74.
46. Laconi, E.; Doratiotto, S.; Vineis, P. The microenvironments of multistage carcinogenesis. Semin. Cancer Biol., 2008, 18, 322-9.
47. Itano, N.; Kimata, K. Altered hyaluronan biosynthesis in cancer progression. Semin. Cancer Biol., 2008, 18, 268-74.
48. Boregowda, R. K.; Appaiah, H. N.; Siddaiah, M.; Kumarswamy, S. B.; Sunila, S.; Thimmaiah, K. N.; Mortha, K.; Toole, B.; Banerjee, S. Expression of hyaluronan in human tumor progression. J.Carcinog., 2006, 5, 2.
49. Yamada, Y.; Itano, N.; Narimatsu, H.; Kudo, T.; Morozumi, K.; Hirohashi, S.; Ochiai, A.; Ueda, M.; Kimata, K. Elevated transcript level of hyaluronan synthase1 gene correlates with poor prognosis of human colon cancer. Clin. Exp. Metastasis, 2004, 21 , 57-63.
50. Bharadwaj, A. G.; Rector, K.; Simpson, M. A. Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis. J. Biol. Chem., 2007, 282, 20561-72.
51. Itano, N.; Sawai, T.; Miyaishi, O.; Kimata, K. Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res. 1999, 59, 2499-504.
52. Enegd, B.; King, J. A.; Stylli, S.; Paradiso, L.; Kaye, A. H.; Novak, U. Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery, 2002, 50, 1311-8.
53. Lokeshwar, V. B.; Lokeshwar, B. L.; Pham, H. T.; Block, N. L. Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res., 1996, 56, 651-7.
54. Pham, H. T.; Block, N. L.; Lokeshwar, V. B. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res., 1997, 57, 778-83.
55. Franzmann, E. J.; Schroeder, G. L.; Goodwin, W. J.; Weed, D. T.; Fisher, P.; Lokeshwar, V. B. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int. J. Cancer, 2003, 106, 438-45.
56. Toole, B. P.; Ghatak, S.; Misra, S. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr. Pharm. Biotechnol., 2008, 9, 249-52.
57. Obayashi, Y.; Yabushita, H.; Kanyama, K.; Noguchi, M.; Zhuo, L.; Kimata, K.; Wakatsuki, A. Role of serum-derived hyaluronanassociated protein-hyaluronan complex in ovarian cancer. Oncol. Rep., 2008, 19, 1245-51.
58. Day, A. J.; de la Motte, C. A. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol., 2005, 26, 637-43.
59. Hascall, V. C.; Majors, A. K.; De La Motte, C. A.; Evanko, S. P.; Wang, A.; Drazba, J. A.; Strong, S. A.; Wight, T. N. Intracellular hyaluronan: a new frontier for inflammation? Biochim. Biophys. Acta, 2004, 1673, 3-12.
60. Toole, B. P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer, 2004, 4, 528-39.
61. Yu, Q.; Toole, B. P.; Stamenkovic, I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med., 1997, 186, 1985-96.
62. Fujita, Y.; Kitagawa, M.; Nakamura, S.; Azuma, K.; Ishii, G.; Higashi, M.; Kishi, H.; Hiwasa, T.; Koda, K.; Nakajima, N.; Harigaya, K. CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett., 2002, 528, 101-8.
63. Zhang, Y.; Thant, A. A.; Machida, K.; Ichigotani, Y.; Naito, Y.; Hiraiwa, Y.; Senga, T.; Sohara, Y.; Matsuda, S.; Hamaguchi, M. Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res., 2002, 62, 3962-5.
64. Bourguignon, L. Y. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J. Mamm. Gland. Biol. Neoplasia, 2001, 6, 287-97.
65. Toole, B. P.; Slomiany, M. G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin. Cancer Biol., 2008, 18, 244-50.
66. Misra, S.; Ghatak, S.; Zoltan-Jones, A.; Toole, B. P. Regulation of multidrug resistance in cancer cells by hyaluronan. J. Biol. Chem., 2003, 278, 25285-8.
67. Cordo Russo, R. I.; Garcia, M. G.; Alaniz, L.; Blanco, G.; Alvarez, E.; Hajos, S. E. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int. J. Cancer, 2008, 122, 1012-8.
68. Camenisch, T. D.; McDonald, J. A. Hyaluronan: is bigger better? Am. J. Respir. Cell Mol. Biol., 2000, 23, 431-3.
69. Herrera-Gayol, A.; Jothy, S. Effect of hyaluronan on xenotransplanted breast cancer. Exp. Mol. Pathol., 2002, 72, 179-85.
70. Charrad, R. S.; Li, Y.; Delpech, B.; Balitrand, N.; Clay, D.; Jasmin, C.; Chomienne, C.; Smadja-Joffe, F. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat. Med., 1999, 5, 669-76.
71. Alaniz, L.; Rizzo, M.; Malvicini, M.; Jaunarena, J.; Avella, D.; Atorrasagasti, C.; Aquino, J. B.; Garcia, M.; Matar, P.; Silva, M.; Mazzolini, G. Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Cancer Lett., 2009, 278, 9-16.
72. Rabinovich, G. A.; Gabrilovich, D.; Sotomayor, E. M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol., 2007, 25, 267-96.
73. Mummert, M. E. Immunologic roles of hyaluronan. Immunol. Res., 2005, 31, 189-206.
74. Siegelman, M. H.; DeGrendele, H. C.; Estess, P. Activation and interaction of CD44 and hyaluronan in immunological systems. J. Leukoc. Biol., 1999, 66, 315-21.
75. Mahaffey, C. L.; Mummert, M. E. Hyaluronan synthesis is required for IL-2-mediated T cell proliferation. J. Immunol., 2007, 179, 8191-9.
76. Noble, P. W.; Lake, F. R.; Henson, P. M.; Riches, D. W. Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages. J. Clin. Invest., 1993, 91, 2368-77.
77. McKee, C. M.; Penno, M. B.; Cowman, M.; Burdick, M. D.; Strieter, R. M.; Bao, C.; Noble, P. W. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J. Clin. Invest. 1996, 98, 2403-13.
78. Yamawaki, H.; Hirohata, S.; Miyoshi, T.; Takahashi, K.; Ogawa, H.; Shinohata, R.; Demircan, K.; Kusachi, S.; Yamamoto, K.; Ninomiya, Y. Hyaluronan receptors involved in cytokine induction in monocytes. Glycobiology, 2009, 19, 83-92.
79. Ruffell, B.; Johnson, P., Hyaluronan induces cell death in activated T cells through CD44. J. Immunol., 2008, 181, 7044-54.
80. Bollyky, P. L.; Lord, J. D.; Masewicz, S. A.; Evanko, S. P.; Buckner, J. H.; Wight, T. N.; Nepom, G. T. Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J. Immunol., 2007, 179, 744-7.
81. Huarte, E.; Tirapu, I.; Arina, A.; Vera, M.; Alfaro, C.; Murillo, O.; Palencia, B.; Busto, V.; Marin, V.; Mazzolini, G.; Melero, I. Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin. Biol. Ther., 2005, 5, 7-22.
82. Palucka, A. K.; Ueno, H.; Fay, J. W.; Banchereau, J. Taming cancer by inducing immunity via dendritic cells. Immunol. Rev., 2007, 220, 129-50.
83. Mazzolini, G.; Alfaro, C.; Sangro, B.; Feijoo, E.; Ruiz, J.; Benito, A.; Tirapu, I.; Arina, A.; Sola, J.; Herraiz, M.; Lucena, F.; Olague, C.; Subtil, J.; Quiroga, J.; Herrero, I.; Sadaba, B.; Bendandi, M.; Qian, C.; Prieto, J.; Melero, I. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J. Clin. Oncol., 2005, 23, 999-1010.
84. Tuyaerts, S.; Aerts, J. L.; Corthals, J.; Neyns, B.; Heirman, C.; Breckpot, K.; Thielemans, K.; Bonehill, A. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother., 2007, 56, 1513-37.
85. Do, Y.; Nagarkatti, P. S.; Nagarkatti, M. Role of CD44 and hyaluronic acid (HA) in activation of alloreactive and antigen-specific T cells by bone marrow-derived dendritic cells. J. Immunother., 2004, 27, 1-12.
86. Mummert, M. E.; Mummert, D.; Edelbaum, D.; Hui, F.; Matsue, H.; Takashima, A. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J. Immunol., 2002, 169, 4322-31.